top of page
  • Recruiting

NCT05121103: Phase 1: A Study in Subjects With Relapsed/Refractory Multiple Myeloma and RR DLBCL

Updated: May 24, 2022

NCT05121103: Phase 1: A Study in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma

EZM0414

A Study in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma


This is a first-in-human (FIH), 2-part, open-label, multi-center, Phase 1/1b safety, tolerability, pharmacokinetics (PK), and efficacy study of oral SETD2 inhibitor, EZM0414, in subjects with relapsed/refractory (R/R) Multiple Myeloma (MM) and R/R Diffuse Large B-Cell Lymphoma (DLBCL).


Sponsor


Multiple Locations

 

ClinicalTrials.gov Identifier: NCT05121103


Official Title: A Phase 1/1b, Open-Label, Multi-Center, Two-Part Study of SETD2 Inhibitor EZM0414 in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma


First Posted : November 16, 2021


Click here to see details on ClinicalTrials.gov

 

Drug: EZM0414

 

SETD2 Inhibitor EZM0414 (Code C185420)

EZM 0414

EZM-0414

EZM0414

SETD2 Inhibitor EZM0414

 

Locations

United States, Maryland

United States, Massachusetts

United States, New Jersey

United States, New York

United States, Texas

United States, Virginia





Comments


Posts Archive
bottom of page